This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sprangers, M. C. Articles by Kostense, S. Search for Related Content PubMed PubMed Citation Articles by Sprangers, M. C. Articles by Kostense, S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2003, p. 5046-5052, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5046-5052.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

Vaccine R&D Division, Crucell Holland BV, 2301 CA Leiden, The Netherlands

Received 7 November 2002/ Returned for modification 29 March 2003/ Accepted 1 September 2003

The presence of various levels of anti-adenovirus serotype 5 (Ad5)-neutralizing antibodies in humans is thought to contribute to the inconsistent clinical results obtained so far in diverse gene transfer and vaccination studies and might preclude universal dosing with recombinant Ad5. Prescreening of individuals eligible for Ad5 or alternative serotype treatment and subsequently tailoring the vector dose might aid in ensuring the consistency of clinical parameters. For this purpose, a qualified Ad neutralization assay is required. Here we have tested the different protocols used to date to determine anti-Ad neutralizing activity. Based on simplicity, speed, high throughput, sensitivity, and robustness, we propose a qualified assay in which Ad neutralization is monitored by luciferase reporter gene expression.

This article has been cited by other articles:

• Liu, J., Ewald, B. A., Lynch, D. M., Denholtz, M., Abbink, P., Lemckert, A. A. C., Carville, A., Mansfield, K. G., Havenga, M. J., Goudsmit, J., Barouch, D. H. (2008). Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys. J. Virol. 82: 4844-4852 [Abstract] [Full Text]  
• Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., O'Brien, K. L., Carville, A., Mansfield, K. G., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2007). Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. J. Virol. 81: 4654-4663 [Abstract] [Full Text]  
• Thorner, A. R., Lemckert, A. A. C., Goudsmit, J., Lynch, D. M., Ewald, B. A., Denholtz, M., Havenga, M. J. E., Barouch, D. H. (2006). Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity. J. Virol. 80: 12009-12016 [Abstract] [Full Text]  
• Thorner, A. R., Vogels, R., Kaspers, J., Weverling, G. J., Holterman, L., Lemckert, A. A. C., Dilraj, A., McNally, L. M., Jeena, P. M., Jepsen, S., Abbink, P., Nanda, A., Swanson, P. E., Bates, A. T., O'Brien, K. L., Havenga, M. J. E., Goudsmit, J., Barouch, D. H. (2006). Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-saharan Africa.. J. Clin. Microbiol. 44: 3781-3783 [Abstract] [Full Text]  
• Lemckert, A. A. C., Grimbergen, J., Smits, S., Hartkoorn, E., Holterman, L., Berkhout, B., Barouch, D. H., Vogels, R., Quax, P., Goudsmit, J., Havenga, M. J. E. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.. J. Gen. Virol. 87: 2891-2899 [Abstract] [Full Text]  
• Verhaagh, S., de Jong, E., Goudsmit, J., Lecollinet, S., Gillissen, G., de Vries, M., van Leuven, K., Que, I., Ouwehand, K., Mintardjo, R., Weverling, G. J., Radosevic, K., Richardson, J., Eloit, M., Lowik, C., Quax, P., Havenga, M. (2006). Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J. Gen. Virol. 87: 255-265 [Abstract] [Full Text]  
• Ophorst, O. J. A. E., Radosevic, K., Havenga, M. J. E., Pau, M. G., Holterman, L., Berkhout, B., Goudsmit, J., Tsuji, M. (2006). Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice. Infect. Immun. 74: 313-320 [Abstract] [Full Text]  
• Nanda, A., Lynch, D. M., Goudsmit, J., Lemckert, A. A. C., Ewald, B. A., Sumida, S. M., Truitt, D. M., Abbink, P., Kishko, M. G., Gorgone, D. A., Lifton, M. A., Shen, L., Carville, A., Mansfield, K. G., Havenga, M. J. E., Barouch, D. H. (2005). Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys. J. Virol. 79: 14161-14168 [Abstract] [Full Text]  
• Lemckert, A. A. C., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2005). Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity. J. Virol. 79: 9694-9701 [Abstract] [Full Text]  
• Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Essex, M., Walker, B. D., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2005). Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein. J. Immunol. 174: 7179-7185 [Abstract] [Full Text]  
• Santra, S., Seaman, M. S., Xu, L., Barouch, D. H., Lord, C. I., Lifton, M. A., Gorgone, D. A., Beaudry, K. R., Svehla, K., Welcher, B., Chakrabarti, B. K., Huang, Y., Yang, Z.-Y., Mascola, J. R., Nabel, G. J., Letvin, N. L. (2005). Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. J. Virol. 79: 6516-6522 [Abstract] [Full Text]  
• Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A., Gillissen, G., Verhaagh, S., Custers, J., Zuijdgeest, D., Berkhout, B., Bakker, M., Quax, P., Goudsmit, J., Havenga, M. (2004). Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5. J. Virol. 78: 13207-13215 [Abstract] [Full Text]  
• Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., Korioth-Schmitz, B., Newberg, M. H., Gorgone, D. A., Lifton, M. A., Panicali, D. L., Nabel, G. J., Letvin, N. L., Goudsmit, J. (2004). Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity. J. Immunol. 172: 6290-6297 [Abstract] [Full Text]